This cluster-randomized trial in Uganda will evaluate the effectiveness and implementation of a novel, peer-led TB education and counseling strategy to improve outcomes among persons with tuberculosis (TB) with and without HIV/AIDS and assess the social-behavioral mechanisms underlying the observed treatment effects.
Study Design Aim 1. The investigators will conduct a parallel cluster-randomized hybrid Type 2 effectiveness-implementation trial at 16 sites. Aim 2. Within the Aim 1 study, the investigators will nest a longitudinal observational study in both arms of the cluster-randomized trial to determine the feasibility, acceptability, and appropriateness of a peer-navigation strategy for TB-EC. The investigators will concurrently assess biological adherence using urine biomarkers) and will also perform a mediation analysis of social and behavioral factors (i.e., TB knowledge, perceived social support, general self-efficacy, HIV/TB stigma) to identify causal mechanisms of impact. Finally, the investigators will pilot and culturally adapt study instruments in a pilot study prior to the trial. Aim 3. The investigators will also conduct a qualitative and mixed methods studies to assess the implementation fidelity and context of the peer-navigation strategy for TB-EC: 1. Process evaluation of intervention fidelity to quantify the adoption, reach, implementation, and maintenance of the peer navigation strategy, 2. In-depth interviews with people with Tuberculosis (PWTB) with and without HIV, 3. In-depth interviews with and direct observation of peer navigators, and 4. Focus-group discussions (FGDs) with healthcare workers. The focus of this registration is Aim 1 and 2.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Enrollment
1,920
Standard TB-EC by healthcare workers
multi-component, peer-navigation strategy for TB-EC
Primary Care Clinics
Kampala, Uganda
Effectiveness assessed by TB treatment completion
The number of participants with TB treatment completion, defined by WHO as attending all refill visits and completing 180 daily doses of standard TB treatment within 8 months of TB treatment initiation, as documented in the on-site TB treatment register.
Time frame: up to 8 months post TB treatment initiation
Effectiveness assessed by Antiretroviral Therapy (ART) retention
The number of participants with ART retention, defined as completing all ART refill visits (or refill pickups if enrolled in differentiated models of ART care) and continuing on daily ART 12 months after starting ART, as documented in the on-site ART register.
Time frame: month 12 post ART initiation
Clinical Effectiveness assessed by TB recurrence-free survival
Clinical Effectiveness assessed by the number of participants with 6-month post-treatment TB recurrence-free survival. Data collectors at all sites will telephone participants and/or treatment supporters to document TB recurrence-free survival.
Time frame: month 6 post TB-treatment
Clinical Effectiveness assessed by HIV RNA copy number
Clinical Effectiveness assessed by the number of participants with 12-month HIV RNA ≤50 copies/mL.
Time frame: month 12 post ART initiation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.